Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

Abstract

Background: Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment.However, real clinical practice is still limited. Objectives:To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods:We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).Results: Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2.Conclusions: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.

Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma

“…Among 67 CTCL patients from the Spanish Primary Cutaneous Lymphoma Registry, ORR was 63% in MF, 71% in SS, and 84% in other CD30+ lymphoproliferative disorders. 47 Similar ORR rates (69% and 62%, respectively) were reported in a retrospective analysis from nine European Organization for Research and Treatment of Cancer (EORTC) centers. The median duration of response (DOR) was 9 months, with higher ORR in the skin (72%) than in the lymph nodes (47%) or blood (40%).…”

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

“…Currently, the favoured treatment for cases of extracutaneous involvement in pcALCL, characterised by the N1 peripheral lymph nodes, is multidrug chemotherapy based on the CHP (cyclophosphamide, doxorubicin, prednisone) or CHOP (CHP + vincristine) regimen. However, the preferred regimen for N1 cALCL is BV with or without local radiotherapy [44,[66][67][68][69][70][71][72]. Duvic et al presented the results of the treatment with brentuximab vedotin conducted in 48 patients, of which 11 were diagnosed with pcALCL or LyP (2 with pcALCL, 9 with LyP), the remaining patients suffered from MF CD30+, LyP/MF, pcALCL/LyP or pcALCL/MF [67].…”

CD30 in Cutaneous Pathology

“…124 It is out of the topic of this article to evaluate the major impact that the anti-CD30 approach has had on the survival and management of the many CD30-positive diseases. Just as a summary, not only many CD30 + lymphomas may benefit from this therapy [125][126][127] but also it seems to be a promising treatment for systemic mastocytosis. 128,129 In the past few years, an additional targeting therapy against CD30 + lymphomas has been developed by using CAR T cells.…”